Abstract:Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Herein, we report a near-infrared imaging probe for TNBC detection via visualizing class I HDACs. Conjugating Cy5.5 to a cyclic depsipeptide inhibitor, we obtained the probe (20-Cy5.5) that retained desirable class I HDAC affinity and selectivity. Then, this probe could visualize epigenetic changes by class I HDACs in TNBC MDA-MB-231 cells and in xenograft tumor models in real time. Treatment with suberoylanilide hydroxamic acid (SAHA) significantly reduced the uptake of the probe in tumors, suggesting its potential use in evaluation of therapeutic responses of HDACi-mediated therapy. Moreover, 20-Cy5.5 could detect class I HDAC expression in TNBC lung metastasis. This novel NIR probe that achieves tumor class I HDAC imaging not only leads to a better understanding of epigenetic regulation in tumors but also has great potential for improving the TNBC diagnosis and treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02161?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02161</a>.Chemistry and general methods; molecular modeling; HDAC inhibition assay by cyclic depsipeptides and 20-Cy5.5; cell culture and antiproliferation assay; breast tumor xenograft and metastatic tumor model; in vitro fluorescence microscopic studies; in vivo and ex vivo optical imaging studies; immunohistochemistry; therapeutic evaluation study; and statistical analysis (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_001.pdf">PDF</a>)SMILES formula of each tested compound and associated biochemical data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_002.csv">CSV</a>)Compound 9 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_003.pdb">PDB</a>)Compound 10 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_004.pdb">PDB</a>)This article has not yet been cited by other publications.

Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer

Non-fused imidazole-biphenyl analogs repress triple-negative breast cancer growth by mainly stabilizing the c-MYC G-quadruplex via a multi-site binding mode

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Selective stabilization of multiple promoter G-quadruplex DNA by using 2-phenyl-1H-imidazole-based tanshinone IIA derivatives and their potential suppressing function in the metastatic breast cancer

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy Against Breast Cancer

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer

Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Quinazoline-based Hydroxamic Acid Derivatives As Dual Histone Methylation and Deacetylation Inhibitors for Potential Anticancer Agents.

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays

Rational design of small-molecules to recognize G-quadruplexes of c-MYC promoter and telomere and the evaluation of their in vivo antitumor activity against breast cancer

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer